Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 8Breast 8Genitourinary 7Gastrointestinal 7Classical hematology 2Sarcoma 1Plasma cell 1Other neoplasm 1Other hematologic neoplasm 1Lymphoid 1Head & Neck 1Dermatologic 1CNS 1

Conditions

Sarcoma 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Melanoma 1Kidney Neoplasms 1Colorectal Neoplasms 1Breast Neoplasms 1

Interventions

Radiotherapy 221Cyclophosphamide 211Doxorubicin 210Temozolomide 182Ifosfamide 121Filgrastim 111Imatinib Mesylate 104Etoposide 101Vincristine 92Gemcitabine 89Bevacizumab 83Magnetic Resonance Spectroscopy 81Irinotecan 79pembrolizumab 75Radiation 70Carboplatin 65Methotrexate 62pazopanib 61Nivolumab 58Cisplatin 58fludarabine phosphate 57Surgical Procedures, Operative 57Peripheral Blood Stem Cell Transplantation 57Specimen Handling 56Trabectedin 52Docetaxel 50Biopsy 50Busulfan 49Melphalan 46Paclitaxel 44

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Genetic Counseling × Sarcoma × Clear all
NCT05225428 2026-05-22

VERDI

Dana-Farber Cancer Institute

Phase NA Recruiting
1,020 enrolled
BreastDermatologicGastrointestinalGenitourinaryGynecologicSarcoma

Breast Neoplasms, Kidney Neoplasms, Melanoma, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Sarcoma, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡